Progress of cell membrane-derived biomimetic nanovesicles for cancer phototherapy

Raza, Faisal; Zafar, Hajra; Jiang, Liangdi; Su, Jing; Yuan, Weien; Qiu, Mingfeng; Paiva-Santos, Ana Cláudia

doi:10.1039/d3bm01170d

Cited by 4 publications

(1 citation statement)

References 278 publications

(369 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This capability facilitates intercellular communication, coordinates biological functions, and helps maintain homeostasis. 34,35 In the realm of therapeutic applications, researchers have explored the use of EVs derived from macrophages and dendritic cells for immunotherapies. These therapeutic EVs are particularly noted for their role in modulating inflammation and immune responses.…”

Section: Introductionmentioning

confidence: 99%

Functionalized extracellular nanovesicles as advanced CRISPR delivery systems

Wang,

Kong,

Zhuo

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Functionalized extracellular nanovesicles as advanced CRISPR delivery systems

Wang,

Kong,

Zhuo

et al. 2024

Biomater. Sci.

View full text Add to dashboard Cite

show abstract

Revolutionizing Neurocare: Biomimetic Nanodelivery Via Cell Membranes

Liao,

Gong,

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Brain disorders represent a significant challenge in medical science due to the formidable blood‐brain barrier (BBB), which severely limits the penetration of conventional therapeutics, hindering effective treatment strategies. This review delves into the innovative realm of biomimetic nanodelivery systems, including stem cell‐derived nanoghosts, tumor cell membrane‐coated nanoparticles, and erythrocyte membrane‐based carriers, highlighting their potential to circumvent the BBB's restrictions. By mimicking native cell properties, these nanocarriers emerge as a promising solution for enhancing drug delivery to the brain, offering a strategic advantage in overcoming the barrier's selective permeability. We evaluate the unique benefits of leveraging cell membranes from various sources and examine advanced technologies for fabricating cell membrane‐encapsulated nanoparticles capable of masquerading as endogenous cells. This enables the targeted delivery of a broad spectrum of therapeutic agents, ranging from small molecule drugs to proteins, thereby providing an innovative approach to neurocare. Furthermore, the review contrasts the capabilities and limitations of these biomimetic nanocarriers with traditional delivery methods, underlining their potential to enable targeted, sustained, and minimally invasive treatment modalities. We conclude with a perspective on the clinical translation of these biomimetic systems, underscoring their transformative impact on the therapeutic landscape for intractable brain diseases.This article is protected by copyright. All rights reserved

show abstract